Please select an option below to help us tailor your newsletter to best suit your content interests!
Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with HER2-negative, hormone receptor–positive metastatic breast cancer previously treated with a taxane (Abstract GS4-01)…. Read more »
Ari VanderWalde, MD, MPH, Bioeth, West Cancer Center and Research Institute’s Director of Research, stands behind the safety and highly regulated protocols for participants in clinical trials. Dr. VanderWalde recognized the importance and urgency to create a safe and effective vaccine to combat COVID-19. “I had a 50% chance of getting the vaccine and 50%… Read more »
West physicians Dr. Ari VanderWalde, Dr. Axel Grothey, Dr. Daniel Vaena, Dr. Gregorgy Vidal, Dr. Adam ElNaggar, & Dr. Lee Schwartzberg recently published a study on the establishment of a Molecular Tumor Board & Uptake of Recommendations in a Community Setting. Abstract In the precision medicine era, molecular testing in advanced cancer is foundational… Read more »
Gregory Vidal, MD, PhD, West Cancer Center and Research Institute, discusses the methodology of the Neat-HER study on neratinib in the extended adjuvant setting in HER2-positive breast cancer. Gregory Vidal, MD, PhD, of West Cancer Center and Research Institute, discusses the methodology of the Neat-HER study on neratinib in the extended adjuvant setting in… Read more »
OneR and West Cancer Physicians Give Ten Presentations at SABCS OneOncology, the national network of independent oncology practices, announced today that physicians from OneR, the OneOncology Research Network and West Cancer and Research Institute will share results from ten research studies at the San Antonio Breast Cancer Symposium® (SABCS®), an international gathering of physicians and… Read more »
Axel Grothey, MD The New England Journal of Medicine (NEJM) has recently published an editorial entitled “Pembrolizumab as first-line therapy in mismatch repair-deficient advanced colorectal cancer: A new standard of care” written by West Cancer Center’s GI Medical Oncology Lead and GI Oncology Clinical Research Director, Dr. Axel Grothey. Click the link below… Read more »
Matching patient populations with a targetable genomic alteration to a specific investigational study is the aim of a new clinical trial through OneR and Genentech. This partnership will facilitate collaborations on various clinical trials, scientific research and real-world data studies that will advance personalized cancer care at community oncology centers like West. “With too many… Read more »
West Clinic Offering New, Safer Radiation Therapy Options for Prostate Cancer Patients Prostate cancer is the most common cancer in American men, with more than 183,000 new cases diagnosed each year. More than 60,000 American men opt to treat their prostate cancer with radiation every year, but because of the proximity of the rectum… Read more »
West Clinic Offers Patients Even More Oncology Treatment Options West joins launch of new technology platform, OneR, to increase trial therapies for patients As an affiliate of OneOncology, West Clinic now has the ability to further its clinical trial offerings and oncology research knowledge by joining the launch of OneR. OneR is a… Read more »
The 5th Annual West Oncology Conference at Graceland: Advances in the Business and Science of Oncology Special Updates from COA, ASCO, ASH, ASTRO, and ESMO was a valuable forum for the presentation and discussion of new research findings. Participants were provided with an update on practice-changing data on women’s cancers, genitourinary malignancies, disparities in cancer… Read more »